Loss of efficacy of biological therapies in psoriatic patients is a well-known event. Biological switching is common in clinical practice, especially in TNF-α and IL-12/23 inhibitors treatment1,2 . Recently, anti-IL-17A drugs such as secukinumab have provided a new therapeutic opportunity This article is protected by copyright. All rights reserved.
Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience
Stingeni, LConceptualization
;
2019
Abstract
Loss of efficacy of biological therapies in psoriatic patients is a well-known event. Biological switching is common in clinical practice, especially in TNF-α and IL-12/23 inhibitors treatment1,2 . Recently, anti-IL-17A drugs such as secukinumab have provided a new therapeutic opportunity This article is protected by copyright. All rights reserved.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
